This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Mar 1;199(5):766-7; author reply 767.

doi: 10.1086/596746.

Unsuspected and paradoxical potential for drug interaction by rifampin: things to ponder with antiretroviral therapy

Nuggehally R Srinivas

PMID: 19210166
DOI: 10.1086/596746

Comment

Unsuspected and paradoxical potential for drug interaction by rifampin: things to ponder with antiretroviral therapy

Nuggehally R Srinivas. J Infect Dis. 2009.

. 2009 Mar 1;199(5):766-7; author reply 767.

doi: 10.1086/596746.

Author

Nuggehally R Srinivas

PMID: 19210166
DOI: 10.1086/596746

No abstract available

PubMed Disclaimer

Comment on

Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries.
Dooley KE, Flexner C, Andrade AS. Dooley KE, et al. J Infect Dis. 2008 Oct 1;198(7):948-61. doi: 10.1086/591459. J Infect Dis. 2008. PMID: 18713054 Review. No abstract available.

Similar articles

Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.
McIlleron H, Meintjes G, Burman WJ, Maartens G. McIlleron H, et al. J Infect Dis. 2007 Aug 15;196 Suppl 1:S63-75. doi: 10.1086/518655. J Infect Dis. 2007. PMID: 17624828 Review.
Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
Chang SY, Lin SW, Hung CC. Chang SY, et al. Clin Infect Dis. 2009 Nov 1;49(9):1452-3; author reply 1453-4. doi: 10.1086/644494. Clin Infect Dis. 2009. PMID: 19824849 No abstract available.
Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?
Gervasoni C, Riva A, Impagnatiello C, Galli M, Cattaneo D. Gervasoni C, et al. Clin Infect Dis. 2013 Aug;57(3):480-1. doi: 10.1093/cid/cit258. Epub 2013 Apr 24. Clin Infect Dis. 2013. PMID: 23616494 No abstract available.
Funding. Experts look for more to fight TB, HIV/AIDS coinfection.
[No authors listed] [No authors listed] AIDS Policy Law. 2009 Sep;24(10):3. AIDS Policy Law. 2009. PMID: 19827208 No abstract available.
Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings.
Semvua HH, Kibiki GS, Kisanga ER, Boeree MJ, Burger DM, Aarnoutse R. Semvua HH, et al. Ther Drug Monit. 2015 Feb;37(1):22-32. doi: 10.1097/FTD.0000000000000108. Ther Drug Monit. 2015. PMID: 24943062 Review.

See all similar articles

Cited by

Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms.
Srinivas NR. Srinivas NR. Drugs R D. 2016 Jun;16(2):141-8. doi: 10.1007/s40268-016-0133-0. Drugs R D. 2016. PMID: 27098526 Free PMC article. Review.
Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT. Ling SY, et al. Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309. Br J Clin Pharmacol. 2014. PMID: 24330024 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information